ChemoMetec A/S engages in the development and supply of instruments and consumables for life science research and diagnostics. The company’s operational framework consists of the assessment, sales, and service of advanced technologies for cell counti…
Analysis
Quality compounder
ChemoMetec A/S earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 40.4×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 16% a year, against analyst forecasts of 9%. The gap between price and consensus is worth watching: demanding expectations.
Growth is moderate; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202374
62
2023202420252026
All-time high
98
Jan 2025
All-time low
61
Jan 2024
Average rank
77
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
3
1
1
1
Price/Earnings
12
10
10
10
Price/Book
1
1
1
1
Dividend Yield
55
49
64
1
Value (overall)
7
10
10
1
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.